Treatment guidelines for gastrointestinal stromal tumors in children and young adults.

Gastrointestinal stromal tumor (GIST) occurring in the pediatric population has a unique biology and natural history when compared to GIST occurring in adults. As a result of these unique features, management of GIST in children may need to differ from management of GIST in adults. GIST is a very rare disease in children. Consequently prospective clinical trials have not been performed. A review of the biology, clinical presentation and natural history of GIST in children is presented. Guidelines for diagnostic evaluation and management of GIST in children are presented. The presented guidelines are based on clinical experience and data from case reports and case series.

[1]  C. Weldon,et al.  Pediatric gastrointestinal stromal tumor. , 2012, Seminars in pediatric surgery.

[2]  S. Baruchel,et al.  Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study , 2011, Clinical Cancer Research.

[3]  C. Antonescu,et al.  Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations , 2010, Proceedings of the National Academy of Sciences.

[4]  J. Lasota,et al.  Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. , 2009, Archives of pathology & laboratory medicine.

[5]  A. D. Van den Abbeele,et al.  Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib , 2009, Pediatric blood & cancer.

[6]  A. Pappo,et al.  Pediatric gastrointestinal stromal tumors. , 2009, Hematology/oncology clinics of North America.

[7]  K. Owzar,et al.  Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Antonescu,et al.  Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Scarpa,et al.  A systematic review on the clinical diagnosis of gastrointestinal stromal tumors , 2008, Journal of surgical oncology.

[10]  Narasimhan P. Agaram,et al.  Novel V600E BRAF mutations in imatinib‐naive and imatinib‐resistant gastrointestinal stromal tumors , 2008, Genes, chromosomes & cancer.

[11]  S. Hirohashi,et al.  Distinct gene expression-defined classes of gastrointestinal stromal tumor. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Flieder,et al.  Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors , 2008, Proceedings of the National Academy of Sciences.

[13]  R. Go,et al.  Financial conflicts of interest (FCOIs) among the National Comprehensive Cancer Network (NCCN) clinical practice guideline panel members , 2008 .

[14]  Narasimhan P. Agaram,et al.  Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors , 2008, Clinical Cancer Research.

[15]  J. Crowley,et al.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Fletcher,et al.  Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. , 2007, Cancer research.

[17]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[18]  R. DeMatteo,et al.  Combined Surgical and Molecular Therapy: The Gastrointestinal Stromal Tumor Model , 2006, Annals of surgery.

[19]  L. Sobin,et al.  Gastrointestinal Stromal Tumors in Patients With Neurofibromatosis 1: A Clinicopathologic and Molecular Genetic Study of 45 Cases , 2006, The American journal of surgical pathology.

[20]  L. Sobin,et al.  Gastrointestinal Stromal Tumors of the Stomach in Children and Young Adults: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 44 Cases With Long-Term Follow-Up and Review of the Literature , 2005, The American journal of surgical pathology.

[21]  A. Pappo,et al.  Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors (GISTs) , 2005, Pediatric blood & cancer.

[22]  M. van de Rijn,et al.  Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  N. Socci,et al.  Gastrointestinal Stromal Tumors in Children and Young Adults: A Clinicopathologic, Molecular, and Genomic Study of 15 Cases and Review of the Literature , 2005, Journal of pediatric hematology/oncology.

[24]  B. Nilsson,et al.  Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era , 2005, Cancer.

[25]  H. El‐Serag,et al.  The Epidemiology of Malignant Gastrointestinal Stromal Tumors: An Analysis of 1,458 Cases from 1992 to 2000 , 2005, The American Journal of Gastroenterology.

[26]  M. Bernstein,et al.  Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. , 2004, Blood.

[27]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[28]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[29]  J. Fletcher,et al.  Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. , 2002, Human pathology.

[30]  J. Carney,et al.  Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. , 1999, Mayo Clinic proceedings.

[31]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[32]  J. Ellison,et al.  Clinical and molecular genetics of patients with the Carney–Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD , 2008, European Journal of Human Genetics.

[33]  C. Antonescu,et al.  Outcome of Metastatic GIST in the Era before Tyrosine Kinase Inhibitors , 2006, Annals of Surgical Oncology.